Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Trafficking protein particle complex subunit 2 (TRAPPC2) is a component of the TRAPP complex, a multisubunit tethering complex involved in the targeting and fusion of endoplasmic reticulum-to-Golgi transport vesicles. TRAPPC2 (also called sedlin) is required for the export of large cargoes such as procollagen from the endoplasmic reticulum, enabling their subsequent modification in the Golgi apparatus. Mutations in the TRAPPC2 gene cause X-linked spondyloepiphyseal dysplasia tarda, a disease characterized by impaired bone and cartilage development, typically manifesting in males during childhood. TRAPPC2 can interact with proteins such as MBP-1 and Alpha-enolase (ENO1) and may inhibit the transcriptional repression and pro-apoptotic functions of ENO1. No evidence was found that this protein is a direct therapeutic target, nor that any clinically used drugs modulate it.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Trafficking protein particle complex subunit 2 (TRAPPC2).